Sun Pharmaceutical Industries Ltd (SUNPHARMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 948699, "name": "Sun Pharma.Inds.", "stock_name": "Sun Pharma.Inds.", "full_name": "Sun Pharmaceutical Industries Ltd", "name_url": "stocks-analysis/sun-pharmainds", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "1,756.80", "chg": 0.45, "chgp": "0.03%", "dir": 1, "prev_price": "1,756.35", "mcapval": "423,831.00 Cr", "mcap": "Large Cap", "scripcode": 524715, "symbol": "SUNPHARMA", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE044A01036", "curr_date": "Mar 24", "curr_time": "", "bse_nse_vol": "23.56 lacs", "exc_status": "Active", "traded_date": "Mar 24, 2026", "traded_date_str": "2026 03 24", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Sun Pharmaceutical Sees Significant Open Interest Surge Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-significant-open-interest-surge-amid-mixed-market-signals-3910793", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SunPharmaceutic_oi_spurts_by_underlying_3910793.png", "date": "2026-03-24 15:00:42", "description": "Sun Pharmaceutical Industries Ltd (SUNPHARMA) has witnessed a notable 13.37% increase in open interest in its derivatives segment, signalling heightened market activity and shifting positioning among investors. Despite this surge, the stock has underperformed its sector and broader indices over the past two days, reflecting a complex interplay between bullish bets and short-term price pressures." }, { "title": "Sun Pharmaceutical Sees Significant Open Interest Surge Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-significant-open-interest-surge-amid-mixed-market-signals-3910663", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SunPharmaceutic_oi_spurts_by_underlying_3910663.png", "date": "2026-03-24 14:00:36", "description": "Sun Pharmaceutical Industries Ltd has witnessed a notable surge in open interest (OI) in its derivatives segment, reflecting heightened market activity and evolving investor positioning. The 12.9% increase in OI, coupled with robust volume patterns, suggests a strategic shift in directional bets amid a backdrop of mixed price momentum and sector dynamics." }, { "title": "Sun Pharmaceutical Industries Sees Significant Open Interest Surge Amid Rising Market Activity", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-sees-significant-open-interest-surge-amid-rising-market-activity-3910532", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SunPharmaceutic_oi_spurts_by_underlying_3910532.png", "date": "2026-03-24 13:00:26", "description": "Sun Pharmaceutical Industries Ltd has witnessed a notable surge in open interest (OI) in its derivatives segment, with a 10.12% increase to 1,24,861 contracts from 1,13,387 previously. This development, coupled with rising volumes and sustained price momentum near its 52-week high, suggests a shift in market positioning and potential directional bets among investors." }, { "title": "P/E at 34.7 vs Industry's 31.09: What the Data Shows for Sun Pharmaceutical Industries Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-amid-nifty-50-benchmark-dynamics-3909529", "imagepath": "", "date": "2026-03-24 09:21:03", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Valuation Picture: Premium Reflecting Market Confidence?</strong></p>\n <p>The current P/E of 34.7 for <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> stands above the sector average of 31.09, indicating that investors are willing to pay a premium of nearly 11.6% for its earnings. This valuation premium may reflect expectations of superior earnings stability or growth prospects relative to peers. However, it also raises questions about whether the premium is justified given the stock’s recent performance and broader sector dynamics. <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharma</a>’s market capitalisation of ₹4,26,685.73 crore..." }, { "title": "P/E at 35.12 vs Industry's 31.90: What the Data Shows for Sun Pharmaceutical Industries Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-nifty-50-membership-and-institutional-dynamics-shape-market-outlook-3906718", "imagepath": "", "date": "2026-03-23 09:20:59", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Valuation Picture: Premium Above Industry Average</strong></p>\n <p>The stock’s P/E ratio of 35.12 stands approximately 10.1% higher than the sector average of 31.90, signalling that investors are willing to pay a premium for <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> relative to its peers. This premium may reflect expectations of superior earnings growth or a perception of stronger fundamentals compared to the broader Pharmaceuticals & Biotechnology sector. However, such a valuation gap also raises questions about sustainability, especially given the sector’s mixed result performance so far in the current reporting season.</p>\n\n <p><strong>Performance Across Tim..." }, { "title": "Sun Pharmaceutical Industries Ltd Strengthens Position Amid Nifty 50 Dynamics", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-strengthens-position-amid-nifty-50-dynamics-3902452", "imagepath": "", "date": "2026-03-20 09:21:07", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Significance of Nifty 50 Membership</strong></p>\n <p>Being a constituent of the Nifty 50 index confers considerable advantages to Sun Pharmaceutical Industries Ltd, not least in terms of visibility and liquidity. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange of India, serves as a benchmark for institutional and retail investors alike. Inclusion in this elite group often leads to increased demand from index funds and passive investment vehicles, which track the Nifty 50 composition.</p>\n <p>Sun Pharma’s market capitalisation currently stands at a substantial ₹4,18,528 crores, firmly placing it in the large-cap category. This stature not only reflects its scale but also its resilience..." }, { "title": "Sun Pharmaceutical Industries Ltd: Navigating Nifty 50 Membership and Institutional Shifts", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-shifts-3899636", "imagepath": "", "date": "2026-03-19 09:21:15", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Significance of Nifty 50 Membership</strong></p>\n <p>Being part of the Nifty 50 index places Sun Pharmaceutical Industries Ltd at the forefront of India’s equity landscape. This membership not only reflects the company’s market capitalisation and liquidity but also ensures heightened visibility among domestic and global investors. Index inclusion often leads to increased institutional interest, as many mutual funds, exchange-traded funds (ETFs), and passive investment vehicles track the Nifty 50, necessitating allocation to its constituents.</p>\n <p>Sun Pharma’s market capitalisation currently stands at a robust ₹4,25,318.11 crores, firmly categorising it as a large-cap entity. This scale provides the company with a competitive advantage in capita..." }, { "title": "Sun Pharmaceutical Industries Ltd is Rated Buy", "link": "https://www.marketsmojo.com/news/stock-recommendation/sun-pharmaceutical-industries-ltd-is-rated-buy-3898460", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SunPharmaceutic_mojoScore_3898460.png", "date": "2026-03-18 10:10:49", "description": "Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook." }, { "title": "Sun Pharmaceutical Sees Heavy Put Option Activity Ahead of March Expiry", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-heavy-put-option-activity-ahead-of-march-expiry-3898399", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SunPharmaceutic_most_active_stocks_puts_3898399.png", "date": "2026-03-18 10:00:15", "description": "Sun Pharmaceutical Industries Ltd has emerged as one of the most actively traded stocks in the put options segment as the 30 March 2026 expiry approaches, signalling increased bearish positioning or hedging activity among investors. With a significant volume of contracts traded at the ₹1800 strike price, market participants appear to be positioning cautiously despite the stock’s proximity to its 52-week high." } ], "total": 1022, "sid": "948699", "stock_news_url": "https://www.marketsmojo.com/news/No announcements on in the last one month-948699" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release", "datetime": "21-Mar-2026", "details": "Sun Pharma launches its semaglutide injection under the brand names Noveltreat and Sematrinity in India", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "18-Mar-2026", "details": "Newspaper publication for Notice of Postal Ballot", "source": "BSE" }, { "caption": "Shareholder Satisfaction Survey On RTA Services", "datetime": "17-Mar-2026", "details": "Shareholder Satisfaction Survey on RTA Services", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Sun Pharmaceutical Industries Ltd has declared <strong>1100%</strong> dividend, ex-date: 05 Feb 26", "dt": "2026-02-05", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:5</strong> stock split, ex-date: 25 Nov 10", "dt": "2010-11-25", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 29 Jul 13", "dt": "2013-07-29", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Valuation Picture: Premium Reflecting Market Confidence?

The current P/E of 34.7 for Sun Pharmaceutical Industries Ltd stands above the sector average of 31.09, indicating that investors are willing to pay a premium of nearly 11.6% for its earnings. This valuation premium may reflect expectations of superior earnings stability or growth prospects relative to peers. However, it also raises questions about whether the premium is justified given the stock’s recent performance and broader sector dynamics. Sun Pharma’s market capitalisation of ₹4,26,685.73 crore...

Read full news article

P/E at 35.12 vs Industry's 31.90: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-03-23 09:20:59

Valuation Picture: Premium Above Industry Average

The stock’s P/E ratio of 35.12 stands approximately 10.1% higher than the sector average of 31.90, signalling that investors are willing to pay a premium for Sun Pharmaceutical Industries Ltd relative to its peers. This premium may reflect expectations of superior earnings growth or a perception of stronger fundamentals compared to the broader Pharmaceuticals & Biotechnology sector. However, such a valuation gap also raises questions about sustainability, especially given the sector’s mixed result performance so far in the current reporting season.

Performance Across Tim...

Read full news article

Sun Pharmaceutical Industries Ltd Strengthens Position Amid Nifty 50 Dynamics
2026-03-20 09:21:07

Significance of Nifty 50 Membership

Being a constituent of the Nifty 50 index confers considerable advantages to Sun Pharmaceutical Industries Ltd, not least in terms of visibility and liquidity. The index, representing the top 50 companies by free-float market capitalisation on the National Stock Exchange of India, serves as a benchmark for institutional and retail investors alike. Inclusion in this elite group often leads to increased demand from index funds and passive investment vehicles, which track the Nifty 50 composition.

Sun Pharma’s market capitalisation currently stands at a substantial ₹4,18,528 crores, firmly placing it in the large-cap category. This stature not only reflects its scale but also its resilience...
Read full news article
Sun Pharmaceutical Industries Ltd: Navigating Nifty 50 Membership and Institutional Shifts
2026-03-19 09:21:15

Significance of Nifty 50 Membership

Being part of the Nifty 50 index places Sun Pharmaceutical Industries Ltd at the forefront of India’s equity landscape. This membership not only reflects the company’s market capitalisation and liquidity but also ensures heightened visibility among domestic and global investors. Index inclusion often leads to increased institutional interest, as many mutual funds, exchange-traded funds (ETFs), and passive investment vehicles track the Nifty 50, necessitating allocation to its constituents.

Sun Pharma’s market capitalisation currently stands at a robust ₹4,25,318.11 crores, firmly categorising it as a large-cap entity. This scale provides the company with a competitive advantage in capita...
Read full news article
Sun Pharmaceutical Industries Ltd is Rated Buy
2026-03-18 10:10:49
Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read full news article
Sun Pharmaceutical Sees Heavy Put Option Activity Ahead of March Expiry
2026-03-18 10:00:15
Sun Pharmaceutical Industries Ltd has emerged as one of the most actively traded stocks in the put options segment as the 30 March 2026 expiry approaches, signalling increased bearish positioning or hedging activity among investors. With a significant volume of contracts traded at the ₹1800 strike price, market participants appear to be positioning cautiously despite the stock’s proximity to its 52-week high.
Read full news article
View All News